216 related articles for article (PubMed ID: 2720576)
1. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM
Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576
[TBL] [Abstract][Full Text] [Related]
2. Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patients.
Goughnour BR; Arkinstall WW; Stewart JH
Cancer; 1989 Jun; 63(11 Suppl):2294-7. PubMed ID: 2720578
[TBL] [Abstract][Full Text] [Related]
3. Control of severe pain with sustained-release morphine tablets v. oral morphine solution.
Arkinstall WW; Goughnour BR; White JA; Stewart JH
CMAJ; 1989 Mar; 140(6):653-7, 661. PubMed ID: 2645988
[TBL] [Abstract][Full Text] [Related]
4. The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects.
Kaiko RF; Grandy RP; Oshlack B; Pav J; Horodniak J; Thomas G; Ingber E; Goldenheim PD
Cancer; 1989 Jun; 63(11 Suppl):2348-54. PubMed ID: 2720580
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a cancer pain model for the testing of long-acting analgesics. The effect of MS Contin in a double-blind, randomized crossover design.
Cundiff D; McCarthy K; Savarese JJ; Kaiko R; Thomas G; Grandy R; Goldenheim P
Cancer; 1989 Jun; 63(11 Suppl):2355-9. PubMed ID: 2720581
[TBL] [Abstract][Full Text] [Related]
6. Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients.
Portenoy RK; Maldonado M; Fitzmartin R; Kaiko RF; Kanner R
Cancer; 1989 Jun; 63(11 Suppl):2284-8. PubMed ID: 2720577
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.
Gourlay GK; Cherry DA; Onley MM; Tordoff SG; Conn DA; Hood GM; Plummer JL
Pain; 1997 Feb; 69(3):295-302. PubMed ID: 9085304
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
Gourlay GK
Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation.
Khojasteh A; Evans W; Reynolds RD; Thomas G; Savarese JJ
J Clin Oncol; 1987 Jun; 5(6):956-61. PubMed ID: 3585450
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dosing guidelines for the use of oral controlled-release morphine (MS Contin tablets).
Warfield CA
Cancer; 1989 Jun; 63(11 Suppl):2360-4. PubMed ID: 2720582
[TBL] [Abstract][Full Text] [Related]
13. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer.
Walsh TD; MacDonald N; Bruera E; Shepard KV; Michaud M; Zanes R
Am J Clin Oncol; 1992 Jun; 15(3):268-72. PubMed ID: 1590284
[TBL] [Abstract][Full Text] [Related]
14. Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food.
Kaiko RF; Lazarus H; Cronin C; Grandy R; Thomas G; Goldenheim P
Hosp J; 1990; 6(4):17-30. PubMed ID: 2088996
[TBL] [Abstract][Full Text] [Related]
15. A bioequivalence study of oral controlled-release morphine using naltrexone blockade.
Kaiko RF; Grandy RP; Reder RF; Goldenheim PD; Sackler RS
J Clin Pharmacol; 1995 May; 35(5):499-504. PubMed ID: 7657850
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain.
Broomhead A; Kerr R; Tester W; O'Meara P; Maccarrone C; Bowles R; Hodsman P
J Pain Symptom Manage; 1997 Aug; 14(2):63-73. PubMed ID: 9262035
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
18. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine?
Christrup LL; Sjøgren P; Jensen NH; Banning AM; Elbaek K; Ersbøll AK
J Pain Symptom Manage; 1999 Sep; 18(3):164-73. PubMed ID: 10517037
[TBL] [Abstract][Full Text] [Related]
19. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets.
Kaiko RF; Fitzmartin RD; Thomas GB; Goldenheim PD
Pharmacotherapy; 1992; 12(2):107-13. PubMed ID: 1570227
[TBL] [Abstract][Full Text] [Related]
20. Controlled release morphine tablets: a double-blind trial in patients with advanced cancer.
Hanks GW; Twycross RG; Bliss JM
Anaesthesia; 1987 Aug; 42(8):840-4. PubMed ID: 3310722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
